ESTRO 2022 - Abstract Book

S664

Abstract book

ESTRO 2022

Results Presently, data from >11,000 pts included in 58 research projects are collected. Fig. 2 shows a cumulative distribution of treatment dates for pts included in the DcmCollab. Over the years, the inflow of data has been steady. Development of DcmCollab has focused on both adding features and on improving security. The main features now are: • High focus on security • Easy data submission directly from the local TPS • Web upload of data, supporting international participation • Storage of all raw data submitted • Individual structure name mapping schemes for each research project • Display of RT plans and DVH • Creation of anonymized data for quality assurance(QA), e.g. delineation audits

Conclusion The DcmCollab system was created to support and facilitate RT research by storing and managing complete RT planning datasets for national projects and thereby provide a powerful basis to facilitate research. The aforementioned features have been fundamental for the success of DcmCollab, evident by the large amount of data uploaded. Similar features should be considered when developing a similar system. Additionally, the national unique personal identifier, the CPR-number, has facilitated linking data from DcmCollab to other databases, and the SDN network is the basis for the direct data submission from the local TPS. The system has matured over time, and has now become a unique and invaluable database of detailed, high quality RT data. Furthermore, the system has become a valued tool for transferring data, generating datasets for audit trials, and performing QA of data in ongoing trials.

OC-0752 SBRT for lung cancer and lung metastases: prospective national registration project in Belgium.

Y. Lievens 1 , M. Lambrecht 2 , L. Boesmans 3 , H. Engels 4 , X. Geets 5 , S. Janssens 3 , L. Moretti 6 , V. Remouchamps 7 , S. Roosens 8 , N. Van Damme 3 1 Ghent University Hospital and Ghent University, Radiation Oncology Department, Ghent, Belgium; 2 University Hospital Leuven, Radiation Oncology Department, Leuven, Belgium; 3 Belgian Cancer Registry, NA, Brussels, Belgium; 4 Belgian National Institute for Health and Disability Insurance, NA, Brussels, Belgium; 5 Cliniques Universitaires Saint-Luc, Radiation Oncology Department, Brussels, Belgium; 6 Institut Jules Bordet, Université Libre de Bruxelles, Radiation Oncology Department, Brussels, Belgium; 7 CHU UCL Namur, Site Sainte Elisabeth, Radiation Oncology Department, Namur, Belgium; 8 Belgian National Institute for Health and Disability Insurance, NA, Brussels, Belgium Purpose or Objective Stereotactic body radiotherapy (SBRT) is the standard of care for inoperable early-stage non-small cell lung cancer, and is increasingly used to radically treat oligometastatic disease (OMD). Patterns-of-care and survival are reported of primary lung cancer and metastatic lung lesions radically treated with SBRT in a coverage with evidence development (CED) program in Belgium.